Cingulate Revenue and Competitors

Location

$0.509M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Cingulate's total funding is $0.509M.

Employee Data

  • Cingulate has 18 Employees.(i)
  • Cingulate grew their employee count by -5% last year.

Cingulate's People

NameTitleEmail/Phone
1
Co-founder Board DirectorsReveal Email/Phone
2
Chairman, CEOReveal Email/Phone
3
Chief Financial OfficerReveal Email/Phone
4
Chief Medical OfficerReveal Email/Phone
5
Chief Science OfficerReveal Email/Phone
6
VP, Operations and Quality AssuranceReveal Email/Phone
7
VP, Investor & Public Relations; VP, Government AffairsReveal Email/Phone
8
VP, Clinical OperationsReveal Email/Phone
9
Director, Manufacturing Operations & Drug Product DevelopmentReveal Email/Phone
10
Member Board DirectorsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$10.3M4610%N/AN/A
#2
$24.7M99-3%N/AN/A
#3
$5.6M259%N/AN/A
#4
$26.7M12211%N/AN/A
#5
$4.4M196%N/AN/A
#6
$74.6M3080%N/AN/A
#7
$22.7M941%N/AN/A
#8
N/A18-5%$509KN/A
#9
$12.3M858%$20MN/A
#10
$3.8M15-6%N/AN/A
Add Company

What Is Cingulate?

Cingulate® is a biopharmaceutical company utilizing its innovative Precision Timed Release™ (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. \n \nWe aim to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. \n \nWith an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), we believe there are multiple therapeutic areas where our PTR technology may be employed to develop additional product candidates, notably anxiety disorders.

keywords:N/A

$0.509M

Total Funding

18

Number of Employees

N/A

Revenue (est)

-5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.7M18-61%N/A
#2
$8.5M18-18%N/A
#3
$1.6M18N/AN/A
#4
$2.4M1850%N/A
#5
$1.6M186%N/A